Menu

FDA Declares Kratom an Opioid. We’re Here to Explain What It Does.

The Scientist speaks with a clinical toxicologist to discuss how the supplement acts in the brain and what the agency's declaration means for research.

Feb 7, 2018
Jim Daley

ISTOCK, AR30MM

The Food and Drug Administration (FDA) announced on Tuesday (February 6) that kratom, a popular herbal supplement, is a dangerous drug with “opioid properties.” The announcement came after the FDA evaluated the potential for kratom abuse using the Public Health Assessment via Structural Evaluation (PHASE) methodology, which simulates the molecular structures of a substance using 3-D computer modeling.

“[W]e feel confident in calling compounds found in kratom, opioids,” FDA Commissioner Scott Gottlieb declared in the statement. “And it’s an opioid that’s associated with novel risks because of the variability in how it’s being formulated, sold and used recreationally and by those who are seeking to self-medicate for pain or who use kratom to treat opioid withdrawal symptoms.”

Clinical toxicologist Oliver Grundmann of the University of Florida coauthored a study in 2017 on the neuropharmacology of kratom and its potential for abuse. He spoke with The Scientist about the plant and the FDA’s announcement.

Oliver Grundmann

The Scientist:  Commissioner Gottlieb declared kratom was an opioid that is not safe for medical use. Can you tell me how kratom works pharmacologically?

Grundmann: At low concentrations, if you take it you get more of a stimulant effect; in higher concentrations you get more of an analgesic, opioid-like effect. So, there’s a dose-dependent distinction in its effects.

The likely opioid-like compounds, or the compounds that act on the opioid receptors, are mitragynine and 7-hydroxy mitragynine. These are the two that have been currently identified and where extensive research is available. . . .

On the molecular level, what we know in terms of interaction with the different opioid receptors is that yes, they bind to the opioid receptor. . . . But how they interact with the opioid receptor is distinctly different from classical opioids. If you look at morphine or at something like fentanyl . . .  what we usually look at when we classically look at opioid receptors, these are G-protein-coupled receptors, where basically the morphine or another binding agent binds from the outside to the receptor and then you have a kind of second-messenger cascade that happens inside the cell.

How they interact with the opioid receptor is distinctly different from classical opioids.

Now, what we know about the opioid receptors . . . is that opioid receptors also recruit beta-arrestin. [It] has been shown to be responsible for a lot of the negative effects, especially in regards to respiratory depression and potentially even in regards to the addictive symptoms . . . that are associated with opioid use, misuse, leading to abuse. That is something that mitragynine is not doing. Mitragynine does not recruit beta-arrestin.

TS: Would you say that you agree with the FDA’s classification of [kratom] as affecting the body just like opioids, or no?

Grundmann: The science is on the same page in regards to mitragynine and 7-hydroxy mitragynine and thereby certain compounds in kratom acting on opioid receptors. My concern is . . . we’ve got roughly 5 million kratom users—roughly, it’s a very rough estimate. In my survey that was published in 2017 [I] showed that this is a distinctly different user population from what you would expect to find in opioid users.

I fear that by banning kratom, we are creating a significant issue by hindering research. I am a proponent of regulating kratom as limiting the excess, as controlling products that are entering the United States [to ensure] they show quality, that there is actually kratom inside when kratom is mentioned on the label. I support that health care providers should be serving as intermediaries to provide patients and consumers with advice on what they actually take.

But phasing it into Schedule 1 makes it very hard to further conduct research. And this is a new class of endo-alkaloids that act very distinctly different on opioid receptors. And just because the FDA hasn’t received an NDA [New Drug Application] or IND [Investigational New Drug application] to actually conduct a study with mitragynine to move it into a clinical trial, which we know costs . . . millions of dollars, doesn’t mean that it doesn’t have value for these 4 or 5 million kratom users, who I feel would have to go back to using prescription opioids or potentially going to street drugs.    

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Improved Accuracy in Multiplex Assays

Improved Accuracy in Multiplex Assays

Interference by endogenous antibodies in immunoassays is a well-documented phenomenon. Download this poster to learn about the profound effects that this can have on the data and how development expertise and assay design can eliminate or reduce the effects of endogenous antibodies.

Complete Pathology Solutions: Make Every Minute Count

Complete Pathology Solutions: Make Every Minute Count

From sample collection and handling, to fixation and processing, tissue staining, and covering all your IHC and water purification needs—you can have confidence in the quality of your results with MilliporeSigma's one-stop pathology solution.

Preparing Cell Or Tissue Lysates For ELISA Kits

Preparing Cell Or Tissue Lysates For ELISA Kits

RayBiotech manufactures over 2,000 high fully validated, GMP-compliant ELISA kits. In this blog post we explain how to prepare cell or tissue lysates for ELISA Kits.

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Achieves Illumina Propel Certification as a Service Provider for Next Generation Sequencing

Norgen Biotek Corp., an innovative privately held Canadian biotechnology company focusing primarily on nucleic acid and protein stabilization and purification, as well as providing high quality services to the scientific community, today announced that it has become Propel-Certified through Illumina as a Next Generation Sequencing (NGS) service provider.